Clinical Impact of Patient-Reported Outcomes in cGVHD

EP: 1.Differentiating Acute and Chronic Graft-vs-Host Disease

EP: 2.Navigating Chronic GVHD: Phases of Pathophysiology and Best Practices in Patient Monitoring

EP: 3.Optimizing Chronic GVHD Therapy

EP: 4.Navigating Treatment Decisions in Chronic GVHD

EP: 5.Overview of Advanced Therapies in cGVHD

EP: 6.Overview of the ROCKstar Study

EP: 7.Considerations for Third-Line Treatment in Chronic GVHD

EP: 8.Clinical Scenario: Treatment Selection in the third line and beyond in cGVHD

EP: 9.Recent Updates: REACH3, ROCKstar, and RWD

EP: 10.AGAVE-201: Axatilimab for cGVHD

EP: 11.Emerging Trends in Chronic GVHD: Promising Clinical Trials and the Future Treatment Landscape

Now Viewing

EP: 12.Clinical Impact of Patient-Reported Outcomes in cGVHD

EP: 13.Multidisciplinary Approaches to GVHD

Video content above is prompted by the following:

• What is the role of patient-reported outcomes (PROs) to measure symptom burden, adverse effect burden, and quality of life and treatment response in cGVHD in your practice?

Which PRO measures are most useful for evaluating disease improvement in cGVHD?

• What do results from recently published PRO data for belumosudil show (Lee SJ, et al. Transplant Cell Ther. 2022)?

Also summarize data with ruxolitinib (Zeiser R, et al. N Engl J Med. 2021) and FDA analysis of ibrutinib PRO data (King-Kallimanis BL, et al. Qual Lif Res. 2020).

• How can available PRO data be utilized in clinical practice to improve quality of life of patients with cGVHD?